Free tool
FAERS Monitor: Evotaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206353 or its brand name (Evotaz, Atazanavir Sulfate, Cobicistat). Reports on generic versions are filed under their own applications.
Reports
245
Serious
184
75% of reports
Hospitalization
23
Death reported
16
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain43
- emotional distress40
- anxiety39
- anhedonia36
- osteoporosis25
- chronic kidney disease21
- foetal exposure during pregnancy21
- bone density decreased18
- osteopenia18
- renal failure15
- maternal exposure during pregnancy14
- depression13
- economic problem13
- gait disturbance11
- exposure during pregnancy10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 12 |
| 2016 | 21 |
| 2017 | 36 |
| 2018 | 24 |
| 2019 | 28 |
| 2020 | 34 |
| 2021 | 54 |
| 2022 | 12 |
| 2023 | 20 |
| 2024 | 1 |
| 2025 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,914 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anhedoniaSignal | 36 | 117.8 | 87.1 | 4,051 |
| osteopeniaSignal | 18 | 102.0 | 65.3 | 1,699 |
| economic problemSignal | 13 | 73.7 | 43.4 | 861 |
| osteoporosisSignal | 25 | 52.2 | 36.0 | 1,207 |
| bone density decreasedSignal | 18 | 49.3 | 31.6 | 806 |
| emotional distressSignal | 40 | 28.4 | 21.4 | 1,035 |
| chronic kidney diseaseSignal | 21 | 23.7 | 15.8 | 436 |
| foetal exposure during pregnancySignal | 21 | 22.2 | 14.7 | 405 |
| exposure during pregnancySignal | 10 | 13.8 | 7.5 | 107 |
| maternal exposure during pregnancySignal | 14 | 13.5 | 8.1 | 150 |
| anxietySignal | 39 | 11.8 | 8.8 | 379 |
| renal failureSignal | 15 | 9.7 | 5.9 | 109 |
| painSignal | 43 | 6.0 | 4.6 | 180 |
| gait disturbanceSignal | 11 | 4.9 | 2.8 | 31 |
| depressionSignal | 13 | 4.9 | 2.9 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.